Aptus Pharma IPO

₹1,30,000/2000 shares

Minimum Investment

IPO Details

Open Date

23 Sep 25

Close Date

25 Sep 25

Minimum Investment

₹1,30,000

Lot Size

2000

Price Range

₹65 to ₹70

Listing Exchange

BSE

Issue Size

₹13.02 Cr

Listing Date

30 Sep 25

Open Free Demat Account

Aptus Pharma IPO Timeline

Bidding Start

23 Sep 25

Bidding Ends

25 Sep 25

Allotment Finalisation

26 Sep 25

Refund Initiation

29 Sep 25

Demat Transfer

29 Sep 25

Listing

30 Sep 25

Aptus Pharma Limited

Aptus Pharma Limited, incorporated in 2010, is engaged in marketing and distribution of finished pharmaceutical formulations. The company manufactures and distributes over 194 formulations across more than eleven therapeutic segments including acute therapies, chronic care, wellness, nutraceuticals, and exports through its Aptus Global division. Its products serve antacids, pain management, anti-inflammatories, antibiotics, cardiology, neuropsychiatry, dental, injectables, syrups, and sachets. The company operates from Ahmedabad with a warehouse of 15,732 sq. ft., 125 distributors, and a field sales team of 54 employees, supporting 70 total staff.

Aptus Pharma Limited IPO Overview

The Aptus Pharma IPO is a book-building issue of ₹13.02 crore, consisting entirely of a fresh issue of 0.19 crore shares. The IPO opens for subscription on 23 September 2025 and closes on 25 September 2025, with allotment expected to be finalized on 26 September 2025. The shares will be listed on BSE SME, with a tentative listing date of 30 September 2025. The price band is set at ₹65 to ₹70 per share, and the lot size is 2,000 shares. Retail investors must invest a minimum of ₹2,80,000 for 4,000 shares, while HNI investors must subscribe to a minimum of 3 lots (6,000 shares), amounting to ₹4,20,000. Interactive Financial Services Ltd. is the book running lead manager, Bigshare Services Pvt. Ltd. is the registrar, and Market-Hub Stock Broking Pvt. Ltd. is the market maker.

Aptus Pharma Limited IPO Details

Particulars	Details
IPO Date	23 September 2025 to 25 September 2025
Listing Date	30 September 2025
Face Value	₹10 per share
Issue Price Band	₹65 to ₹70 per share
Lot Size	2,000 Shares
Total Issue Size	18,60,000 shares (aggregating up to ₹13.02 Cr)
Fresh Issue	18,60,000 shares (aggregating up to ₹13.02 Cr)
Offer for Sale	NA
Issue Type	Bookbuilding IPO
Listing At	BSE SME
Share Holding Pre Issue	50,00,000 shares
Share Holding Post Issue	68,60,000 shares
Market Maker Portion	94,000 shares

Aptus Pharma Limited IPO Reservation

Investor Category	Shares Offered
Market Maker	94,000 (5.05%)
QIB	8,80,000 (47.31%)
NII (HNI)	2,66,000 (14.30%)
Retail	6,20,000 (33.33%)
Total	18,60,000 (100%)

Aptus Pharma Limited IPO Lot Size

Application	Lots	Shares	Amount
Retail (Min)	2	4,000	₹2,80,000
Retail (Max)	2	4,000	₹2,80,000
S-HNI (Min)	3	6,000	₹4,20,000
S-HNI (Max)	7	14,000	₹9,80,000
B-HNI (Min)	8	16,000	₹11,20,000

Aptus Pharma Limited IPO Promoter Holding

Shareholding Status	Percentage
Pre-Issue	100%
Post-Issue	72.89%

Aptus Pharma Limited IPO Valuation Overview

KPI	Value
EPS (Pre IPO / Post IPO)	6.20 / 4.52
Price/Earnings (P/E)	11.29 / 15.49
Return on Net Worth (RoNW)	44.50%
Return on Equity (ROE)	44.50%
Return on Capital Employed (ROCE)	45.66%
EBITDA Margin	19.31%
Debt/Equity Ratio	1.49

Objectives of the Proceeds

Capital expenditure for office premises, furniture, and industrial racks – ₹1.63 Cr

Working capital requirements to support operations – ₹8.00 Cr

General corporate purposes to strengthen business – Amount not specified

Key Financials (in ₹ Crores)

Particulars	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	21.92	10.03	6.22
Total Income	24.64	17.88	13.90
Profit After Tax	3.10	0.80	0.19
Reserves and Surplus	1.97	1.47	0.67
Total Borrowing	10.36	5.31	2.21

SWOT Analysis of Aptus Pharma IPO

Strength and Opportunities

Diversified product portfolio across multiple therapeutic segments
Extensive distribution network with 125 direct and sub-distributors
Strategic manufacturing alliances across Gujarat, Uttarakhand, and Himachal Pradesh
Competitive and cost-effective pricing strategy
Experienced management team driving operational and strategic growth

Risks and Threats

High debt-to-equity ratio may increase financial risk
Dependence on regional manufacturing limits geographic diversification
Intense competition in pharmaceutical formulations market
Regulatory changes may impact operational efficiency
Limited international presence restricts export opportunities

Explore IPO Opportunities

Explore our comprehensive IPO pages to stay updated on the latest trends and insights.

Upcoming SME IPOs

Current SME IPOs

Closed SME IPOs

About Aptus Pharma Limited

Aptus Pharma IPO Strengths

Offers a wide-ranging product portfolio covering multiple therapeutic segments and healthcare needs.

Maintains a strong distribution network with extensive reach across regional and national markets.

Has strategic manufacturing partnerships across Gujarat, Uttarakhand, and Himachal Pradesh locations.

Implements competitive and cost-effective pricing strategies to attract diverse customer segments.

Led by an experienced management team with strong industry knowledge and operational expertise.

Peer Comparison

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	P/E (x)	RoNW (%)	P/BV Ratio
Aptus Pharma Limited	5.32	5.32	13.93	–	44.50	–
Peer Group
Zota Health Care Limited	3.16	3.16	110.83	382.12	2.72	10.97
Sunrest Lifescience Limited	4.66	4.66	37.72	10.56	12.36	1.32
Lincoln Pharmaceuticals Limited	41.11	41.11	335.34	13.53	12.26	1.66

How to apply IPO with HDFC SKY?

Follow these simple steps to apply for an IPO through HDFC SKY. Secure your investments and explore new opportunities with ease by accessing the IPOs available on the platform.

1Login to your HDFC SKY Account

2Select Issue

3Enter Number of Lots and your Price.

4Enter UPI ID

5Complete Transaction on Your UPI App